Research Funding Opportunities

About this program

The ALS Association's Hoffman ALS Clinical Trial Awards Program supports early- to mid-stage (phase 1 or 2a) biomarker-driven clinical trials of novel or repurposed ALS therapeutics (disease‑modifying or symptomatic) and imaging tracer development, providing up to $1,000,000 total funding over 2–3 years. Applicants must submit a letter of intent (LOI); only applicants invited after LOI review may submit full proposals, with invited full proposals due February 17, 2026, by 1:00 p.m. U.S. ET. Specific applicant eligibility is not listed in the posting beyond the LOI requirement, so prospective applicants should consult the ALS Association program guidelines for institution- and investigator-level criteria.